Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anthracycline + dexamethasone
- Development stage
- Unknown
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
A combination therapy consisting of anthracycline chemotherapy agents and dexamethasone, a corticosteroid. Anthracyclines (such as doxorubicin, daunorubicin, and idarubicin) are cytotoxic agents that intercalate DNA and inhibit topoisomerase II, leading to DNA damage and cell death. Dexamethasone is primarily used in this combination as an antiemetic to prevent chemotherapy-induced nausea and vomiting (CINV). This combination is commonly used in the treatment of breast cancer and acute myelogenous leukemia.
02
Targets
TOP2A (DNA topoisomerase II)GR (Glucocorticoid receptor)DNA
Beyond the preview
Go deeper on anthracycline + dexamethasone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anthracycline + dexamethasone.